SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalNNVC - NanoViricides, Inc.


Previous 10 Next 10 
To: Straynut who wrote (12816)8/24/2020 9:36:54 AM
From: mattstat
   of 12857
 
And of course it has nothing to do with NNVC.

Share RecommendKeepReplyMark as Last Read


To: Straynut who wrote (12816)8/24/2020 9:44:37 AM
From: mattstat
   of 12857
 
Keep pumping this horror show. Do you ever consider the pain you have caused to others?

Share RecommendKeepReplyMark as Last Read


From: patriots709/15/2020 8:26:14 AM
   of 12857
 
This just out:

pittwire.pitt.edu

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: patriots70 who wrote (12819)9/15/2020 4:40:16 PM
From: iamajesuit
   of 12857
 
Excellent article! Just discovered following on Seeking Alpha

Healthcare
Scientists isolate tiny antibody that neutralizes SARS-CoV-2
Sep. 15, 2020 4:19 PM ET|About: Eli Lilly and Company (LLY)|By: Douglas W. House, SA News Editor

Scientists at the University of Pittsburgh School of Medicine (UPMC) have isolated an antibody, dubbed Ab8, that is 10x smaller than a full-sized antibody used in drugs and completely neutralizes the SARS-CoV-2 virus.

The data, published in the journal Cell, showed that Ab8 was highly effective in preventing and treating COVID-19 in mice and hamsters.

The scientists says Ab8's small size increases its potential for diffusion in tissues, increasing efficacy, while being potentially suitable for alternative routes of administration such as inhalation. A bonus is that it does not bind to human cells, thereby avoiding unwanted side effects.

Ab8 was identified by "fishing" in a pool of more than 100B potential candidates using the SARS-CoV-2 spike protein as bait. It is created when the VH domain is fused to part of the immunoglobulin tail region, adding the immune functions of a full-sized antibody without the bulk.

Abound Bio, a newly formed UPMC-backed company, has in-licensed the rights to Ab8 for global development.

Selected tickers: Eli Lilly (NYSE: LLY), Gilead Sciences (NASDAQ: GILD), Vir Biotechnology (NASDAQ: VIR), Regeneron Pharmaceuticals (NASDAQ: REGN)

Share RecommendKeepReplyMark as Last Read


From: Savant9/16/2020 7:26:53 AM
   of 12857
 
planning....possibly...
NanoViricides (NYSEMKT: NNVC) perks up 7% premarket on light volume in reaction to its announcement that it has selected a drug candidate, dubbed NV-CoV-1-R, for the treatment of COVID-19.

The company says NV-CoV-1-R consists of a nanoviricide, NV-CoV-1 with Gilead Sciences' (NASDAQ: GILD) remdesivir encapsulated inside its core, adding that NV-CoV-1 is designed to attack the virus particles themselves and "possibly" would also attack infected cells that express a coronavirus antigen called S-protein. Normal cells, which would not display the S-protein, would be unaffected. The encapsulation of remdesivir, it claims, may protect it from rapid metabolism, increasing its stability and effectiveness.

Clinical trials are planned.

Shares are down 34% over the past six months.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Savant who wrote (12821)9/16/2020 7:41:54 AM
From: old 'n cranky
   of 12857
 
it has selected a drug candidate

Not merely selected, NOMINATED.

NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19
finance.yahoo.com

Who gets to vote in the Primaries?

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: old 'n cranky who wrote (12822)9/16/2020 7:44:06 AM
From: Savant
   of 12857
 
Too many candidates to choose one or two or three

But they don't have to run against an incumbent

Share RecommendKeepReplyMark as Last Read


From: mattstat9/16/2020 10:00:33 AM
   of 12857
 
This stock is the quintessential pump and dump.

Share RecommendKeepReplyMark as Last Read


To: old 'n cranky who wrote (12815)9/16/2020 3:59:04 PM
From: HardToFind
   of 12857
 
They're fishing for a lead plaintiff and taking longer to catch one than it should take.
If only they would open up their lawsuit to corporate behavior over the last 15 years instead of just 9 months, I could be quite helpful. (Hell...I think I have an audio of their lawyer lying to me during an annual shareholder meeting Q&A, certainly making a blatantly deceptive statement.)

But I used the last speculative Covid-19 bounce to sell out at $12, so I can't really claim I have been harmed by their recent drug campaign...although whoever I sold my shares to was certainly adversely affected. (Sorry about that...)

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: HardToFind who wrote (12825)9/16/2020 7:16:31 PM
From: HardToFind
   of 12857
 
I think the class-action attorneys have another problem: NNVC has minimal money and/or assets. It could be a long walk from the courthouse to the bank. Maybe they could get some of those invaluable NNVC shares?

Share RecommendKeepReplyMark as Last ReadRead Replies (1)
Previous 10 Next 10